Clone:
REA1199
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
AD2, gp37

Specifications for CD165 Antibody, anti-human, REAfinity™

Overview

Clone REA1199 recognizes the human CD165 antigen, also known as AD2, which is 37–42 kDa cell surface glycoprotein expressed on most thymocytes, thymic epithelial cells, most platelets, fibroblasts, acute T-lymphoblastic leukemia cells (T-ALL cells), central nervous system neurons, islet cells of the pancreas, and Bowman´s capsule of the kidney. CD165, which is similar to TALLA-1 (CD231, T-cell acute lymphoblastic leukemia antigen), plays a role in cell adhesion between thymocytes and thymic epithelial cells during development.
Additional information: Clone REA1199 displays negligible binding to Fc receptors.

Alternative names

AD2, gp37

Detailed product information

Technical specifications

CloneREA1199
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hosthuman cell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD165
Alternative names of antigenAD2, gp37
Distribution of antigenfibroblasts, platelets, neurons, leukemia cells, kidney, pancreas
RRIDAB_2801938, AB_2801944, AB_2801939, AB_2801945, AB_2801940, AB_2801946, AB_2801941, AB_2801947, AB_2801942, AB_2801943

Resources for CD165 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD165 Antibody, anti-human, REAfinity™

Publications

  1. Seon, B. K. (1995) Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37. Int. J. Cancer 63(3): 474
  2. Takagi, S. et al. (1995) Identification of a highly specific surface marker of T-cell acute lymphoblastic leukemia and neuroblastoma as a new member of the transmembrane 4 superfamily. Int. J. Cancer 61(5): 706-715

Related products for
CD165 Antibody, anti-human, REAfinity™

1 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?